The strong interim efficacy and safety data de-risk GX-03 in atopic dermatitis. Watch for the Jefferies presentation on June 4 and any FDA meeting announcements for further upside. The high vehicle response rate (65% EASI-50) is a caution, but GX-03 showed incremental depth improvement.
Price Chart
Executive Summary
Turn Therapeutics reported positive interim Phase 2 data for GX-03 in moderate-to-severe atopic dermatitis, showing rapid and deep efficacy responses (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with no safety concerns. The company is optimizing the trial and preparing FDA interactions, presenting at Jefferies on June 4. This is a significant derisking catalyst for the candidate.
Key Facts
- 92.6% of GX-03-treated subjects achieved EASI-50 at week 4 vs 65.2% for vehicle
- 70.4% achieved EASI-75 at week 4
- 44.4% achieved EASI-90 at week 4 vs 30.4% for vehicle
- 51.9% achieved EASI-90 at week 8 vs 34.8% for vehicle
- No treatment-related serious adverse events, tolerability issues, or discontinuations
- Interim analysis informed trial optimization; enrollment nearing completion
- Company preparing FDA interactions; data to be presented at Jefferies Global Healthcare conference on June 4, 2026
Financial Impact
Not specified
Risk Factors
- High placebo/vehicle response may dilute treatment effect in later-stage trials
- Small sample size (50 subjects) limits statistical reliability
- Clinical-stage company with no revenue; financing risk remains
- Regulatory pathway uncertain; FDA interactions pending
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063177 |
| Document: ea029288001ex99-1.htm | 0001213900-26-063177 |
| Document: 0001213900-26-063177-index-headers.html | 0001213900-26-063177 |
| Document: 0001213900-26-063177-index.html | 0001213900-26-063177 |
| Document: 0001213900-26-063177.txt | 0001213900-26-063177 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $10.47 | awaiting T+60 | — | $10.47 (+0.00%) |
Oct 6, 2026 20d ago | 8-K | $12.10 | awaiting T+60 | — | $10.47 (−13.47%) |
Sep 10, 2026 6w ago | 8-K | $13.38 | awaiting T+60 | — | $10.47 (−21.75%) |
Sep 9, 2026 6w ago | 8-K | $13.75 | awaiting T+60 | — | $10.47 (−23.85%) |
Aug 18, 2026 10w ago | 8-K | $9.99 | awaiting T+60 | — | $10.47 (+4.80%) |
Jul 7, 2026 16w ago | 8-K | $9.71 $14.39 | ▲ +48.20% | ▲ +46.20% | $10.47 (+7.83%) |
Jun 3, 2026 20w ago | 8-K | $6.02 $10.11 | ▲ +67.94% | ▲ +65.44% | $10.47 (+73.92%) |
Jun 1, 2026 21w ago | 8-K | $6.33 $9.73 | ▲ +53.71% | ▲ +52.48% | $10.47 (+65.40%) |
May 27, 2026 21w ago | 8-K | $5.29 $9.54 | ▲ +80.34% | ▲ +78.46% | $10.47 (+97.92%) |
May 19, 2026 23w ago | 8-K | $4.55 $9.86 | ▲ +116.70% | ▲ +110.41% | $10.47 (+130.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers